Search Results for: homologous use

FDA on Key Stem Cell Regulatory Issues & Its Own Research

FDA3

It’s been a seemingly rather quiet year on the FDA regulatory front in the US when it comes to direct-to-consumer stem cell interventions even as the number of dubious stem cell clinics continues to skyrocket. I requested an interview with the FDA to cover the key pressing issues in this arena. I want to thank […]

FDA on Key Stem Cell Regulatory Issues & Its Own Research Read More »

Cell Surgical Network Series Part 3: Key Concerns

Elliot-Lander-and-Mark-berman-300x2331

I recently interviewed Drs. Elliot Lander and Mark Berman of the Cell Surgical Network. It’s an affiliated chain of clinics selling stem cell interventions for more than a dozen medical conditions. You can read Part 1 here and Part 2 here of the interview where we cover 10 important questions. Today is Part 3, where I explain why their answers

Cell Surgical Network Series Part 3: Key Concerns Read More »

Elliot Lander & Mark Berman Interview Part 1: A Window into Cell Surgical Network

The Cell Surgical Network is a large and growing group of affiliated stem cell clinics across the US. The Network providers use stromal vascular fraction (SVF) interventions for a host of conditions on a for-profit basis. Drs. Elliot Lander and Mark Berman lead the Network. They agreed to do a Q&A interview with me. Below is Part 1,

Elliot Lander & Mark Berman Interview Part 1: A Window into Cell Surgical Network Read More »

Wall Street Weirdness Over Stem Cell Biotech Intellicell (SVFC)

Steven-Victor

What the heck is going on with Intellicell Biosystems, Inc. (SVFC, also SVFCE), a stem cell corporation run by Dr. Steven Victor? Why are some on Wall Street seeming so bullish on the company lately? What’s the real story and the facts? What is the key background on this company? Wall Street has been buying

Wall Street Weirdness Over Stem Cell Biotech Intellicell (SVFC) Read More »

Celltex FDA FOIA letter #2: no safety concerns with our stem cells, which really are not drugs

A FOIA request that I made with the FDA in mid-December 2012 has at long last revealed  letters from Celltex  to the FDA that previously were not in the public domain. The reason for the FOIA and for these blog posts is to shed some light on important issues that particularly relate to patient safety. I

Celltex FDA FOIA letter #2: no safety concerns with our stem cells, which really are not drugs Read More »

Leigh Turner Reports Company Precision StemCell To FDA

What is up with the stem cell company, Precision StemCell, these days? I can’t imagine they are exactly celebrating after having been reported to the FDA. They also have apparently moved operations from the US to Colombia at some point recently. What’s the deal here? First, a little background is helpful. In 2012, University of

Leigh Turner Reports Company Precision StemCell To FDA Read More »

Great interview with Lee Buckler on stem cell industry, regulatory issues, and Celltex

Lee Buckler is a true stem cell industry guru. As I’ve been writing this blog for the last couple years it has served as a catalyst for me to meet dozens of really interesting people including. Given all the complex events of late in the stem cell field, I asked Lee if he would do an

Great interview with Lee Buckler on stem cell industry, regulatory issues, and Celltex Read More »